EFFICACY AND SAFETY OF ETRASIMOD IN PATIENTS WITH MODERATE TO SEVERE ISOLATED PROCTITIS RELATIVE TO THOSE WITH MORE EXTENSIVE COLITIS: RESULTS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

Laurent Peyrin-Biroulet  ^{1, 2}     Marla C. Dubinsky  ³     Bruce E. Sands  ³     Julian Panés  ⁴     Stefan Schreiber  ⁵     Walter Reinisch  ⁶     Brian G. Feagan  ^{7, 8}     Silvio Danese  ⁹     Andres Yarur  ¹⁰     Geert R. D'Haens  ¹¹     Martina Goetsch  ¹²     Karolina Wosik  ¹³     Joseph Wu  ¹⁴     Irene Modesto  ¹⁵     Aoibhinn McDonnell  ¹⁶     Lauren Bartolome  ¹⁷     Christopher J. Rabbat  ¹⁷     Severine Vermeire  ^18    
1 University of Lorraine, CHRU-Nancy, Nancy, France
² University of Lorraine, Inserm, NGERE, Nancy, France
³ Icahn School of Medicine at Mount Sinai, New York, United States
⁴ Formerly Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain
⁵ University Hospital Schleswig-Holstein, Kiel University, Kiel, Germany
⁶ Medical University of Vienna, Vienna, Austria
⁷ Western University, London, Canada
⁸ Alimentiv Inc, London, Canada
⁹ IRCCS San Raffaele Hospital and Vita Salute San Raffaele University, Milan, Italy
¹⁰ Inflammatory Bowel Disease Center and Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, United States
¹¹ Amsterdam University Medical Centers, Amsterdam, Netherlands
¹² Pfizer AG, Zürich, Switzerland
¹³ Pfizer Canada, Kirkland, Canada
¹⁴ Pfizer Inc, Groton, United States
¹⁵ Pfizer Inc, Madrid, Spain
¹⁶ Pfizer Ltd, Sandwich, United Kingdom
¹⁷ Pfizer Inc, New York, United States
¹⁸ University Hospitals Leuven, Leuven, Belgium

Topic
IBD

Session
Targeting immune cell trafficking in IBD (Posters)

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)